TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01075334

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porimore - A Carnitine based food supplement
Description: A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
Study: NCT00584831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens
Study: NCT01075334

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc and Folate Supplementation
Description: 500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
Study: NCT03427918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Sex Therapy
Description: Mindfulness-Based Sex Therapy in an integration of psychoeducation, sex therapy, and mindfulness-based skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Sex Therapy
Description: Mindfulness-Based Sex Therapy in an integration of psychoeducation, sex therapy, and mindfulness-based skills.
Study: NCT03285321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg
Study: NCT03226067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GKT137831
Description: GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GKT137831
Description: GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Matching capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching capsules.
Study: NCT00954213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIR/Floortime parent intervention
Description: Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
Study: NCT01845155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro-Music-Therapy according to the Heidelberg Model
Description: The neuro-music therapy according to the Heidelberg Model for tinnitus is a manualized short term music therapeutic treatment lasting for nine consecutive 50-minutes sessions of individualized therapy. Therapy takes place on five consecutive days (from Monday to Friday) with two therapy sessions per day. It comprises both active and receptive forms of music therapy. The interventions are structured into the following modules Directive Counseling, Resonance Training, Neuroauditive Cortex Training, Tinnitus Reconditioning.~For more details on the music therapy see Argstatter et al. 2012

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling
Description: Duration: single session of 50 min Tinnitus specific procedures: The counseling group receives the identical counselling procedure as the music therapy group.
Study: NCT04522297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine/Octreotide
Description: oral midodrine plus octreotide as subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nor-epinephrine
Description: Intravenous infusion norepinephrine
Study: NCT00584831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens
Study: NCT02653196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy
Description: Allogeneic hematopoietic stem cell transplant (HSCT) following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keratinocyte Growth Factor
Description: KGF 60 mcg/kg IV: 6 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa 300 mg/m2 IV: 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m2 IV: 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 IV: 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 70 mg/m2 IV: Day 2 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age \> 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
Study: NCT01299233

Intervention type: DEVICE
Intervention: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
Description: Measurement of the peripapillar nerve fiber layer with different settings of ART

Intervention type: DEVICE
Intervention: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
Description: Measurement of the peripapillar nerve fiber layer with different settings of ART
Study: NCT03252821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: High-intensity interval training sessions will be conducted on cycle ergometers or treadmill with heart rate measured throughout each session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: Resistance exercise will be performed on eight exercises targeting major muscle groups at 60% to 85% of their estimated one-repetition maximum (1RM).
Study: NCT00306592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG00002 (natalizumab)
Study: NCT01302964

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will receive placebo for duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
Study: NCT01347190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR002 Liquid API
Description: A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
Study: NCT00584831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens
Study: NCT01347190

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
Study: NCT02204254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequence
Description: Associated to arm radiofrequence

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline
Description: doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
Study: NCT03899610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy+Durvalumab+Tremelimumab
Description: 1. Neoadjuvant treatment:~   Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~2. Interval debulking surgery~3. Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)
Study: NCT00989729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological Saline
Description: A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
Study: NCT03138668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Injection
Description: All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Injection
Description: All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
Study: NCT00968175

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided celiac plexus neurolysis (CPN)
Description: Initial procedure and rescue procedure if applicable
Study: NCT00596011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenon E
Description: Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo BID
Study: NCT02661438

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to Ciprofloxacin DPI (BAYQ3939)
Description: Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
Study: NCT00584831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens
Study: NCT01588002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: multiple oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: multiple oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: multiple oral doses
Study: NCT01588002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: multiple oral doses
Study: NCT01479907

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotics
Description: 12 gr in 250 cc of water once daily X 15 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 gr in 250 cc of water once daily X 15 days
Study: NCT00215774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide
Description: Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide
Description: Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
Study: NCT01440322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens with color
Description: Silicone hydrogel contact lens with color

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B contact lens
Description: Silicone hydrogel contact lens
Study: NCT03237234

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Motor Skill Training
Description: Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Skill Training
Description: Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: The tDCS electrode placement is based on procedures shown to improve gait and balance in a single session when used in combination with gait training activities. tDCS electrodes can simultaneously activate the bilateral leg motor areas when placed at the midline of the scalp slightly anterior to the vertex (anode) and at the inion (cathode), with a current intensity of 2mA. The tDCS device is lightweight, and can be worn in a backpack during the MT activities. As reported previously, participants in the MT-only group will receive sham tDCS to maintain analogous study procedures.
Study: NCT04118010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: High-dose vitamin D3 50,000 IU /week for 12 weeks
Study: NCT00584831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens
Study: NCT04118010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: High-dose vitamin D3 50,000 IU /week for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo vitamin D3
Description: Matching to Vitamin D3 placebo capsules for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vitamin D3
Description: Matching to Vitamin D3 placebo capsules for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Chicory-derived prebiotic inulin 12 g/day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Chicory-derived prebiotic inulin 12 g/day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inulin
Description: Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inulin
Description: Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks
Study: NCT04659070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental : Ezetimibe / Rosuvastatin + Telmisartan
Description: Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator1 : Ezetimibe / Rosuvastatin
Description: Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator2 : Telmisartan
Description: Telmisartan 80mg PO, Once daily for 8 weeks
Study: NCT00393055

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: xylitol
Description: 1g xylitol lozenges to be dissolved in mouth. Five lozenges daily for three years

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: inactive lozenge
Description: 1g inactive lozenge, dissolved in mouth. Five/day for three years
Study: NCT04537806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexanolone
Description: Administered as IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as IV infusion.
Study: NCT02548988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Selective Neuromuscular Electrical Stimulation on VMO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Selective Neuromuscular Electrical Stimulation on VMO